A hormone secreted by the adrenal cortex that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Aldosterone. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldosterone. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Aldosterone. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldosterone. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldosterone. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Aldosterone. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Aldosterone. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Aldosterone. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Aldosterone. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Aldosterone. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Aldosterone. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldosterone. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Aldosterone. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Aldosterone. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Aldosterone. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Aldosterone. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Aldosterone. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Aldosterone. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Aldosterone. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Aldosterone. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Aldosterone. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Aldosterone. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Aldosterone. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Aldosterone. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Aldosterone. |
| Cladribine | Aldosterone may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Aldosterone. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Aldosterone. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Aldosterone. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Aldosterone. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Aldosterone. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Aldosterone. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Aldosterone. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Aldosterone. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Aldosterone. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Aldosterone. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Aldosterone. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Aldosterone. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Aldosterone. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Aldosterone. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Aldosterone. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Aldosterone. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Aldosterone. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Aldosterone. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Aldosterone. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Aldosterone. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Aldosterone. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Aldosterone. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Aldosterone. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Aldosterone. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Aldosterone. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Aldosterone. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Aldosterone. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Aldosterone. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Aldosterone. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Aldosterone. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Aldosterone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Aldosterone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Aldosterone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Aldosterone. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Aldosterone. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Aldosterone. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Aldosterone. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Aldosterone. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Aldosterone. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Aldosterone. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Aldosterone. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Aldosterone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Aldosterone. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Aldosterone. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Aldosterone. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Aldosterone. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aldosterone. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Aldosterone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Aldosterone. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Aldosterone. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Aldosterone. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Aldosterone. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Aldosterone. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Aldosterone. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Aldosterone. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Aldosterone. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Aldosterone. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Ifosfamide is combined with Aldosterone. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Aldosterone. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Aldosterone. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Aldosterone. |
| Docetaxel | The risk or severity of adverse effects can be increased when Docetaxel is combined with Aldosterone. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Aldosterone. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Aldosterone. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Aldosterone. |
| Stepronin | The risk or severity of adverse effects can be increased when Stepronin is combined with Aldosterone. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Aldosterone. |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with Aldosterone. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Aldosterone. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Aldosterone. |
| Brequinar | The risk or severity of adverse effects can be increased when Brequinar is combined with Aldosterone. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Aldosterone is combined with Pirfenidone. |
| Belinostat | The risk or severity of adverse effects can be increased when Aldosterone is combined with Belinostat. |
| Trabectedin | The risk or severity of adverse effects can be increased when Aldosterone is combined with Trabectedin. |